PURPOSE: Acute liver failure (ALF) and acute on chronic liver failure (ACLF) still show a poor prognosis. MARS was used in 22 patients with ALF or ACLF to prolong patient survival for liver function recovery or as a bridge to transplantation. DESIGN: Evaluation of depurative efficiency, biocompatibility, hemodynamics, encephalopathy (HE) and clinical outcome. PROCEDURES: During 71 five-hour sessions we evaluated (0', 60', 120', 180', 240', 300'): bilirubin, ammonia, cholic acid (CCA), chenodeoxycholic acid (CCDCA), leukocytes, platelets, hemoglobin and mean arterial pressure (MAP). Serum creatinine, electrolytes, cardiac output, cardiac index (bioimpedence) and HE (West Haven Criteria score) were evaluated at 0' and 300'. STATISTICAL METHODS AND OUTCOME MEASURES: Student's t-test for pre- vs. end-session values was used. For bilirubin and ammonia the correlation test was made between pre- and end-session values and between pre-session values and removal rates (RRS). MAIN FINDINGS: Survival was 90.9% at 7 days, 40.9% at 30 days. Pre- vs. end-session: bilirubin from 37.2 +/- 12.5 mg/dL to 24.9 +/- 8.9 mg/dL (p < 0.01), ammonia from 88.0 +/- 60.4 micromol/L to 43.6 +/- 32.9 micromol/L (p < 0.01), CCA from 42.8 +/- 21.0 micromol/L 18.2 +/- 9.8 micromol/L (p < 0.01), CCDCA from 26.3 +/- 6.3 micromol/L to 15.7+/-7.6 micromol/L (p<0.01). The correlation test between pre-session values of bilirubin and ammonia vs. RR S was respectively 0.32 (p = 0.01) and 0.30 (p = 0.04). Leukocytes, platelets and hemoglobin remained stable. MAP increased from 82.0 +/- 12.0 mmHg to 87.0 +/- 13.0 mmHg (p < 0.05), West Haven Criteria score decreased from 2.7 +/- 0.7 to 0.7 +/- 0.7 (p < 0.001). CONCLUSION: MARS treatment led in all patients to an improvement of clinical, hemodynamic and neurological conditions, with significant reduction in the hepatic toxins blood level. Treatment biocompatibility and tolerance were satisfactory.

Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients / Stefoni, Sergio; Coli', Luigi; Bolondi, Luigi; Donati, Gabriele; Ruggeri, Giovanni; Feliciangeli, Giorgio; Piscaglia, Fabio; Silvagni, Elena; M., Sirri; Donati, Gabriele; Baraldi, Olga; Soverini, Maria Letizia; Cianciolo, Giuseppe; Boni, Paola; Patrono, Daniela; E., Ramazzotti; Motta, Roberto; Roda, Aldo; Simoni, Patrizia; Magliulo, Maria; Borgnino, Luigi Carlo; Ricci, Davide; D., Mezzopane; Cappuccilli, Maria. - In: INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS. - ISSN 0391-3988. - 29:2(2006), pp. 207-218. [10.1177/039139880602900207]

Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients

DONATI, GABRIELE;
2006

Abstract

PURPOSE: Acute liver failure (ALF) and acute on chronic liver failure (ACLF) still show a poor prognosis. MARS was used in 22 patients with ALF or ACLF to prolong patient survival for liver function recovery or as a bridge to transplantation. DESIGN: Evaluation of depurative efficiency, biocompatibility, hemodynamics, encephalopathy (HE) and clinical outcome. PROCEDURES: During 71 five-hour sessions we evaluated (0', 60', 120', 180', 240', 300'): bilirubin, ammonia, cholic acid (CCA), chenodeoxycholic acid (CCDCA), leukocytes, platelets, hemoglobin and mean arterial pressure (MAP). Serum creatinine, electrolytes, cardiac output, cardiac index (bioimpedence) and HE (West Haven Criteria score) were evaluated at 0' and 300'. STATISTICAL METHODS AND OUTCOME MEASURES: Student's t-test for pre- vs. end-session values was used. For bilirubin and ammonia the correlation test was made between pre- and end-session values and between pre-session values and removal rates (RRS). MAIN FINDINGS: Survival was 90.9% at 7 days, 40.9% at 30 days. Pre- vs. end-session: bilirubin from 37.2 +/- 12.5 mg/dL to 24.9 +/- 8.9 mg/dL (p < 0.01), ammonia from 88.0 +/- 60.4 micromol/L to 43.6 +/- 32.9 micromol/L (p < 0.01), CCA from 42.8 +/- 21.0 micromol/L 18.2 +/- 9.8 micromol/L (p < 0.01), CCDCA from 26.3 +/- 6.3 micromol/L to 15.7+/-7.6 micromol/L (p<0.01). The correlation test between pre-session values of bilirubin and ammonia vs. RR S was respectively 0.32 (p = 0.01) and 0.30 (p = 0.04). Leukocytes, platelets and hemoglobin remained stable. MAP increased from 82.0 +/- 12.0 mmHg to 87.0 +/- 13.0 mmHg (p < 0.05), West Haven Criteria score decreased from 2.7 +/- 0.7 to 0.7 +/- 0.7 (p < 0.001). CONCLUSION: MARS treatment led in all patients to an improvement of clinical, hemodynamic and neurological conditions, with significant reduction in the hepatic toxins blood level. Treatment biocompatibility and tolerance were satisfactory.
2006
29
2
207
218
Molecular Adsorbent Recirculating System (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients / Stefoni, Sergio; Coli', Luigi; Bolondi, Luigi; Donati, Gabriele; Ruggeri, Giovanni; Feliciangeli, Giorgio; Piscaglia, Fabio; Silvagni, Elena; M., Sirri; Donati, Gabriele; Baraldi, Olga; Soverini, Maria Letizia; Cianciolo, Giuseppe; Boni, Paola; Patrono, Daniela; E., Ramazzotti; Motta, Roberto; Roda, Aldo; Simoni, Patrizia; Magliulo, Maria; Borgnino, Luigi Carlo; Ricci, Davide; D., Mezzopane; Cappuccilli, Maria. - In: INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS. - ISSN 0391-3988. - 29:2(2006), pp. 207-218. [10.1177/039139880602900207]
Stefoni, Sergio; Coli', Luigi; Bolondi, Luigi; Donati, Gabriele; Ruggeri, Giovanni; Feliciangeli, Giorgio; Piscaglia, Fabio; Silvagni, Elena; M., Sirri; Donati, Gabriele; Baraldi, Olga; Soverini, Maria Letizia; Cianciolo, Giuseppe; Boni, Paola; Patrono, Daniela; E., Ramazzotti; Motta, Roberto; Roda, Aldo; Simoni, Patrizia; Magliulo, Maria; Borgnino, Luigi Carlo; Ricci, Davide; D., Mezzopane; Cappuccilli, Maria
File in questo prodotto:
File Dimensione Formato  
Stefoni_IJAO 2006.pdf

Accesso riservato

Dimensione 7.28 MB
Formato Adobe PDF
7.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1256458
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 24
social impact